WHAT WE DO
Abilita Therapeutics is an innovation-driven biotechnology company focused on enabling discovery and development of drugs targeting challenging membrane proteins, including G Protein-Coupled Receptors (GPCRs) and ion channels
Drug discovery targeting multi-span membrane proteins is inherently difficult due to the notoriously low stability and high conformational flexibility of these target classes, especially when removed from the cellular environment.
This intrinsic characteristic of membrane proteins has greatly limited the success of protein-based small molecule screening and structure-guided drug discovery, as well as antibody discovery efforts.
Discovery processes have evolved to utilize purified protein as a reagent to enable cutting edge screening and computational methods.
Membrane protein targets have largely been left behind due to difficulties in expression and purification linked to instability. Even more so, discovery of biologics has been hampered by similar difficulties for most classes of multi-span membrane proteins.